Get started
Author

Samyukta Chillara

Observed name: S. Chillara
Institution: Solti
ORCID: 0000-0002-6072-5455
Observed ORCID: 0000-0002-6072-5455
OpenAlex ID: A5096170099
Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19
2021 · Sascha Jung, Ilya Potapov, et al. · Science Advances · 26
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
2024 · Sonia Pernas, Esther Sanfeliu, et al. · npj Breast Cancer · 6
PDF
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)
2026 · Tomás Pascual, Maria Vidal, et al. · Nature Communications · 5
PDF
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2025 · Mafalda Oliveira, Eva Ciruelos, et al. · Clinical Cancer Research · 4
PDF
Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)
2025 · Mafalda Oliveira, Tomás Pascual, et al. · Clinical Cancer Research · 4
Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024 · Mafalda Oliveira, Tomás Pascual, et al. · Cancer Research · 1
279P Genomic and clinicopathological characterization of early-stage invasive lobular breast cancer: A pooled analysis of SOLTI preoperative trials
2026 · M.A. Bergamino, G. Villacampa, et al. · ESMO Open
Supplementary Figure S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Data S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Figure S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Data S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Table S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Figure S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Table S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Table S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Data from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Figure S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
Supplementary Data S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2026 · Mafalda Oliveira, Eva Ciruelos, et al.
191MO Combination of talimogene laherparepvec (T-VEC) with atezolizumab (atezo) in patients (pts) with residual breast cancer (BC) after standard neoadjuvant chemotherapy (NAC): Survival results of the SOLTI-PROMETEO study
2025 · T. Pascual, M.J. Vidal Losada, et al. · ESMO Open
PDF
Works count: 20
Citation count: 46
H-index: 4
I10-index: 1
Year
Topic
Type